Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 68
- Registration Number
- NCT00213980
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- HealthPartners Institute
- Target Recruit Count
- 72
- Registration Number
- NCT00202059
- Locations
- 🇺🇸
Park Nicollet Institute, St. Louis Park, Minnesota, United States
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 1071
- Registration Number
- NCT00193856
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺St George Hospital, Kogarah, New South Wales, Australia
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00181584
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 218
- Registration Number
- NCT00172055
- Locations
- 🇧🇪
Novaris Investigative Site, Libramont, Belgium
🇧🇪Novartis Investigative Site, Woluwe-Saint-Lambert, Belgium
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
- Conditions
- Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT00172016
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1065
- Registration Number
- NCT00171340
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇹🇭Ratchathew, Khonkaen, Thailand
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
- Conditions
- Multiple Myeloma Stage I
- Interventions
- Drug: Zoledronic acidDietary Supplement: Calcium / Vitamin D
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 143
- Registration Number
- NCT00171925
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT00171314
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00172003
- Locations
- 🇩🇪
Novartis investigative Site, Offenbach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.